H1 receptor antagonist. Outline of commercial prepn: Chem. Week 79 (5), 70 (Aug. 4, 1956); Morren, US 2899436 (1959 to UCB). Pharmacology and metabolism: Cannizaro, Boll. Chim. Farm. 104, 39 (1965); Close et al., Ind. Chim. Belge 33, 94 (1968); eidem, Proc. Eur. Soc. Study Drug Toxic. 9, 144 (1968); S. F. Pong, C. L. Huang, J. Pharm. Sci. 63, 1527 (1974). Pharmacokinetics and antihistaminic activity: F. E. R. Simons et al., J. Allergy Clin. Immunol. 73, 69 (1984); S. Ting et al., ibid. 75, 63 (1985). Clinical trials of efficacy in allergic rhinitis: L. Wong et al., ibid. 67, 223 (1981); in urticaria, R. P. Harvey et al., ibid. 68, 262 (1981); as anti-emetic: R. McKenzie et al., Anesth. Analg. 60, 783 (1981); as pre-surgical sedative: G. Wallace, L. J. Mindlin, ibid. 63, 571 (1984). Toxicity data: E. I. Goldenthal, Toxicol. Appl. Pharmacol. 18, 185 (1971). Comprehensive description: J. Tsau, N. DeAngelis, Anal. Profiles Drug Subs. 7, 319-341 (1978).
Anxiolytic. Antihistaminic.
Antihistaminic; Piperazines; Anxiolytic